A Prospective, Multicenter, Phase 2 Study of Mosunetuzumab in Combination With Zeprumetostat for the Treatment of Follicular Lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 2
- 主要终点
- Best Complete Response (CR) Rate (Cohort 1 and Cohort 3)
研究概览
简要总结
The purpose of this prospective, multicenter, Phase 2 study is to evaluate the efficacy and safety of Mosunetuzumab in combination with the EZH2 inhibitor Zeprumetostat (SHR2554) in patients with follicular lymphoma (FL). The study plans to enroll approximately 80 patients, who will be assigned to three distinct cohorts: previously untreated high-risk FL (Cohort 1), previously untreated low-tumor-burden FL (Cohort 2), and relapsed or refractory FL (Cohort 3). The study consists of a safety run-in phase, which will be initially conducted in Cohort 1 to assess the tolerability of the combination therapy, followed by an expansion phase across all three cohorts to further evaluate the clinical outcomes.
详细描述
This is a prospective, open-label, multicenter, multi-cohort phase 2 study evaluating Mosunetuzumab combined with Zeprumetostat (SHR2554) in follicular lymphoma (FL). The study is conducted in two stages:
Stage 1: Safety Run-in Phase Initially, 6 participants in Cohort 1 will be enrolled to evaluate dose-limiting toxicities (DLTs) during Cycle 1 (28 days). If the safety is acceptable, the study will proceed to Stage 2.
Stage 2: Expansion Phase
Enrollment will expand to three independent cohorts:
Cohort 1: Previously untreated high-risk FL (FLIPI 3-5). Cohort 2: Previously untreated low-tumor-burden FL. Cohort 3: Relapsed or refractory FL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Adequate hematologic and organ function
- •Female subjects of childbearing potential must have a negative serum pregnancy test and agree to use highly effective contraception; male subjects must agree to use effective contraception.
- •Voluntary written informed consent
- •Cohort 1- Previously Untreated High-Risk FL：
- •Histologically confirmed Grade 1-3a follicular lymphoma (FL), CD20-positive, with no evidence of histologic transformation
- •Ann Arbor Stage III/IV
- •No prior systemic therapy for FL
- •Meeting at least one of the GELF criteria for indicating treatment
- •FLIPI-1 or FLIPI-2 score of 3 to 5 (High risk)
- •Cohort 2- Previously Untreated Low-Tumor-Burden FL：
- •Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no prior systemic therapy.
- •Absence of B symptoms or severe pruritus
- •Low tumor burden (LTB) not meeting GELF criteria for treatment
- •Must have at least one measurable lesion (longest diameter >1.5 cm)
- •Patients who are suffering from the disease or prefer active management over a watch-and-wait approach
- •Cohort 3-Relapsed or Refractory FL：
- •Histologically confirmed Grade 1-3a, CD20-positive, Stage III/IV FL with no evidence of histologic transformation.、
- •Relapsed or refractory disease, having received at least 1 prior systemic therapy regimen containing an anti-CD20 antibody
- •No prior treatment with a CD20/CD3 bispecific antibody or an EZH2 inhibitor
- •Presence of at least one measurable or evaluable lesion at relapse
排除标准
- •Central nervous system (CNS) lymphoma, primary mediastinal lymphoma, or evidence of histologic transformation.
- •Uncontrolled cardiovascular, cerebrovascular, coagulopathy, connective tissue, or severe infectious diseases.
- •Pregnant or lactating women.
- •Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) infection (RNA PCR positive).
- •Concurrent other malignancies or history of malignancies, or anti-cancer therapy (including major surgery) within the last 4 weeks.
- •Allergic reaction to the study drugs.
- •Concurrent use of strong CYP3A4 inhibitors or strong CYP3A4 inducers that cannot be avoided
- •Other medical or psychiatric conditions or laboratory abnormalities that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results.
研究组 & 干预措施
Cohort 1: Previously Untreated High-Risk FL
干预措施: Mosunetuzumab (Drug)
Cohort 3: Relapsed or Refractory FL
干预措施: Zeprumetostat (Drug)
Cohort 1: Previously Untreated High-Risk FL
干预措施: Zeprumetostat (Drug)
Cohort 2: Previously Untreated Low-Tumor-Burden FL
干预措施: Mosunetuzumab (Drug)
Cohort 2: Previously Untreated Low-Tumor-Burden FL
干预措施: Zeprumetostat (Drug)
Cohort 3: Relapsed or Refractory FL
干预措施: Mosunetuzumab (Drug)
结局指标
主要结局
Best Complete Response (CR) Rate (Cohort 1 and Cohort 3)
时间窗: Up to approximately 12 months (From start of treatment until the end of up to 12 cycles of treatment)
The best complete response (CR) rate is defined as the percentage of participants who achieve a complete response during the treatment period, as assessed by the investigator according to the Lugano 2014 classification criteria
3-Year Event-Free Survival (EFS) Rate (Cohort 2)
时间窗: Up to 3 years
Event-Free Survival (EFS) is defined as the time from the start of treatment to the first occurrence of any of the following events: progression to high-tumor-burden (HTB) based on GELF criteria, initiation of cytotoxic chemotherapy and/or radiotherapy, histologic transformation, or death from any cause.
次要结局
- Overall Survival (OS)(Up to approximately 5 years)
- Objective Response Rate (ORR) (Cohorts 1, 2, and 3)(Up to approximately 12 months (end of treatment))
- Rate of Progression of Disease within 24 Months (POD24) (Cohorts 1, 2, and 3)(24 months)
- Progression-Free Survival (PFS)(Up to approximately 5 years)
- Incidence and Severity of Adverse Events (AEs)(Up to approximately 5 years)
- Change From Baseline in EORTC QLQ-C30 Score(Baseline up to approximately 5 years)
- Change From Baseline in FACT-Lym LYMS Score(Baseline up to approximately 5 years)